Unity Biotechnology, Inc. (UBX)
NASDAQ: UBX · Real-Time Price · USD
0.960
-0.010 (-1.04%)
Dec 20, 2024, 4:00 PM EST - Market closed
Unity Biotechnology Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
16.17M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nephros | 13.55M |
Spruce Biosciences | 7.10M |
Synlogic | 2.78M |
Palatin Technologies | 2.38M |
Traws Pharma | 226.00K |
UBX News
- 6 weeks ago - UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 4 months ago - UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 5 months ago - UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer - GlobeNewsWire
- 7 months ago - UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 8 months ago - UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting - GlobeNewsWire
- 8 months ago - UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME - GlobeNewsWire
- 8 months ago - UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - GlobeNewsWire
- 11 months ago - New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss - GlobeNewsWire